MRNA
Moderna at key resistance? Moderna
Short Term
We look to Sell at 183.71 (stop at 203.39)
Preferred trade is to sell into rallies. Previous resistance located at 190.00. Trading within a Bearish Channel formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited.
Our profit targets will be 121.74 and 94.19
Resistance: 190.00 / 220.00 / 495.00
Support: 156.00 / 120.00 / 100.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
MRNA has rallied 66% from its bottom MRNA has rallied 66% from its bottom set in mid june.
Technical indicators suggest a strong turnaround.
The P/E ratio and Forward P/E ratio remain in the low single digits.
I boosted my position when the price crossed above the 50 day EMA.
I will take advantage of any pull-back below the 200 day EMA close or low.
Overall, this is still a nice entry point if you wish to go long MRNA for the rest of the decade.
8/3/22 MRNAModerna, Inc. ( NASDAQ:MRNA )
Sector: Health Technology (Biotechnology)
Market Capitalization: $74.178B
Current Price: $186.49
Breakout Price: $189.50
Buy Zone (Top/Bottom Range): $180.95-$147.05
Price Target: $204.50-$208.80 (1st), $258.80-$263.70 (2nd)
Estimated Duration to Target: 34-37d, 91-96d
Contract of Interest: $MRNA 9/16/22 190c, $MRNA 10/21/22 200c
Trade price as of publish date: $13.96/contract, $15.55/contract
BioNTech showing a solid entryBNTX is finally concluding a year long descending triangle pattern. I see a low risk entry at $150 and will be buying. Stop loss set at $138.49, risking about 8.5%. If we see a large move upward, I could see the stock retesting both its 200 day moving average (likely at $183) and its next major resistance after that at $295. A potential of nearly 100% profit (not to say its a sure bet or smart to dump huge amounts into the trade without the stop loss...). Fundamentally, the company has a P/E of 3, no debt, and a huge free cash flow to fund its mrna platforms for a lot of other diseases partnering with some of the largest pharma companies in the world. Yet another variant of covid, upward pressure from the 50and100 day MAs, large portions of the world unvaccinated, and president biden contracting the virus could be potential catalysts for a move. If you're looking for a bio tech exposure this is a stock that seems to be set up well. Good luck to all.
Shooting Star on Moderna? Moderna
Short Term
We look to Sell at 146.42 (stop at 154.23)
Preferred trade is to sell into rallies. Price action has posted a bearish Shooting Star and is negative for short-term sentiment. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited.
Our profit targets will be 122.21 and 94.19
Resistance: 150.00 / 171.76 / 187.50
Support: 120.00 / 100.00 / 66.41
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Feeling sick? (Moderna)Moderna
Short Term
We look to Sell at 133.52 (stop at 141.88)
Preferred trade is to sell into rallies. Prices expected to stall near trend line resistance. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited.
Our profit targets will be 105.41 and 94.19
Resistance: 150.00 / 171.76 / 187.50
Support: 116.00 / 100.00 / 66.41
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Moderna in trouble? Moderna
Short Term - We look to Sell at 149.49 (stop at 160.31)
Preferred trade is to sell into rallies. Closed below the 20-day EMA. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade.
Our profit targets will be 123.84 and 103.50
Resistance: 150.00 / 171.76 / 187.50
Support: 125.00 / 120.00 / 104.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Shorting it to Ground MRNA
We likely see a relief rally which will carry all stocks.
We saw after hour that $FB missed earning but rallied anyway.
Denmark announced today that it is ending all COVID treatment.
thecountersignal.com
Expect other progressive governments to follow suit - although their probably not that many anymore.
Sure you could look at the excess deaths that can't explained and say I'm shorting this experimental drug company.
The attached chart makes a convincing argument. This is a chart of the US excess deaths which can not be explained.
twitter.com - great graphic take a second to view it.
That said I expect Moderna to rally one last time.
I've personally bought back a few options contracts but will be looking to sell more at the .38 Fib at the top the triangle.
Unlike Pfizer which has deep pipeline of drugs - Moderna only has drugs in clinical trials, without the Vaccines they have NO income.
I have very strong feeling about this company but again, I expect it to rally - and from there I will be selling more.
You have to decide for yourself is this doctor lying?
twitter.com
NOTE: stretch this chart out to view it property. Looks good on my 32 DELL monitors but when posted the chart is compressed
BNTX HIGH RISK TO REWARD SETUP YOU CAN'T MISSNews - Better than expected Q4 EPS and sales results, the company expects to authorize a shares repurchase program up to 1.5B over the next two years.
Levels -$195 is the next major resistance level.
$138 is the next major support level.
The stock is gapping up to $183 (pre-market).
The idea is to go long at the open when it will try to test the $183 support level and fail, then go long above the 5M bull flag pattern if it will happen.
Moderna | MRNA | Short, Falling WedgeModerna ( NASDAQ:MRNA ) is in a falling wedge with no signs of escaping (yet). While it may have a small pop if there is good company news, the COVID-19 buying spree may be truly over. The COVID-19 pandemic will soon be an endemic and the market may shift fully away from "COVID-19 tickers". Insiders continue to dump shares. Since the start of 2022, insiders have sold $57 million worth of shares. $10 million of this total in the past 13 days (source: OpenInsider).
I anticipate Moderna to be below $100 in the coming months if it doesn't break the falling wedge's resistance.
PFE Pfizer shortPfizer will re-enter the channel below current support. Looking for a re-test and breakdown of $45 before mid March. Fraud, vaccine ineffectiveness, and blatant disregard for human health are just a few of the concerns here. For those less inclined to believe in science, COVID is over and these vaccine companies cannot rely on any future income comparable to this pandemic.
Moderna: Sell the Break Setup Moderna - Short Term - We look to Sell a break of 137.05 (stop at 147.24)
A move through bespoke support at 140.00 and we look for extended losses. Closed below the 20-day EMA. The primary trend remains bearish. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade.
Our profit targets will be 108.99 and 103.50
Resistance: 150.00 / 170.00 / 200.00
Support: 140.00 / 120.00 / 100.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
PFE still lower to go. Pfizer looks to test $50, and possibly the gap around 46~ if things get really ugly. Omicron is looking really promising as granting significant immunity after infection, which should reduce demand for further vaccinations. These vaccines companies have YEARS of covid priced into their stocks... Short side is getting a bit long in the tooth for new entries, however I am still holding 2/3rds of my puts across the board for these plays.
We posted our short thesis in another thread www.tradingview.com